Drug intelligence / Profile preview

AZD6489

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AZD6489 (formerly IVX-121) is an investigational virus-like particle (VLP) vaccine developed for the prevention of respiratory syncytial virus (RSV) infection, particularly in older adults. The vaccine utilizes a recombinant prefusion conformation of the RSV fusion (F) protein, which is the primary target for potent neutralizing antibodies. By presenting these antigens on a VLP scaffold, AZD6489 aims to mimic the structural presentation of the native virus to elicit a robust and durable immune response. AstraZeneca acquired the asset through its acquisition of Icosavax in early 2024. It is currently being evaluated in Phase I/II clinical trials to characterize its safety and immunogenicity profile in adults aged 60 years and older.

Other names: RSV recombinant prefusion F protein VLP vaccine

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on AZD6489.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD6489.

Explore the full profile